CA2938807A1 - Molecular diagnostic test for predicting response to anti-angiogenic drugs and prognosis of cancer - Google Patents

Molecular diagnostic test for predicting response to anti-angiogenic drugs and prognosis of cancer Download PDF

Info

Publication number
CA2938807A1
CA2938807A1 CA2938807A CA2938807A CA2938807A1 CA 2938807 A1 CA2938807 A1 CA 2938807A1 CA 2938807 A CA2938807 A CA 2938807A CA 2938807 A CA2938807 A CA 2938807A CA 2938807 A1 CA2938807 A1 CA 2938807A1
Authority
CA
Canada
Prior art keywords
sample
expression
biomarkers
subject
biomarker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2938807A
Other languages
English (en)
French (fr)
Inventor
Denis Paul Harkin
Richard Kennedy
Katherine E. Keating
Andrena MCCAVIGAN
Laura A. Hill
Steve Deharo
Timothy Davison
Fionnuala Patterson
Sinead DONEGAN
Gera JELLEMA
Charlie GOURLEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almac Diagnostics Ltd
Original Assignee
Almac Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Diagnostics Ltd filed Critical Almac Diagnostics Ltd
Publication of CA2938807A1 publication Critical patent/CA2938807A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2938807A 2014-02-07 2015-02-09 Molecular diagnostic test for predicting response to anti-angiogenic drugs and prognosis of cancer Abandoned CA2938807A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461937224P 2014-02-07 2014-02-07
US61/937,224 2014-02-07
GBGB1409479.1A GB201409479D0 (en) 2014-05-28 2014-05-28 Molecular diagnostic test for cancer
GB1409479.1 2014-05-28
PCT/GB2015/050352 WO2015118353A1 (en) 2014-02-07 2015-02-09 Molecular diagnostic test for predicting response to anti-angiogenic drugs and prognosis of cancer

Publications (1)

Publication Number Publication Date
CA2938807A1 true CA2938807A1 (en) 2015-08-13

Family

ID=51177582

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2938807A Abandoned CA2938807A1 (en) 2014-02-07 2015-02-09 Molecular diagnostic test for predicting response to anti-angiogenic drugs and prognosis of cancer

Country Status (10)

Country Link
US (1) US10280468B2 (enExample)
EP (1) EP3102700A1 (enExample)
JP (1) JP2017506506A (enExample)
KR (1) KR20160117606A (enExample)
CN (1) CN106164296A (enExample)
AU (1) AU2015213844A1 (enExample)
BR (1) BR112016018044A2 (enExample)
CA (1) CA2938807A1 (enExample)
GB (1) GB201409479D0 (enExample)
WO (1) WO2015118353A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11568982B1 (en) 2014-02-17 2023-01-31 Health at Scale Corporation System to improve the logistics of clinical care by selectively matching patients to providers
US10650325B2 (en) * 2015-07-31 2020-05-12 Microsoft Technology Licensing, Llc Deterministic message distribution
US10496691B1 (en) 2015-09-08 2019-12-03 Google Llc Clustering search results
WO2018062862A1 (ko) * 2016-09-28 2018-04-05 가톨릭대학교 산학협력단 신장암 환자의 예후 진단 및 치료 전략 결정용 성별 특이적 마커
WO2018124153A1 (ja) * 2016-12-28 2018-07-05 公益財団法人がん研究会 抗ｖｅｇｆｒ－２抗体医薬品の治療効果を予測するバイオマーカー、検査方法、及び検査キット
CN107301328B (zh) * 2017-05-19 2021-04-06 浙江工业大学 基于数据流聚类的癌症亚型精准发现与演化分析方法
CN111033631B (zh) * 2017-06-13 2024-03-12 波士顿基因公司 用于生成分子功能谱、对其进行可视化和分类的系统和方法
JP6977965B2 (ja) * 2017-10-26 2021-12-08 公立大学法人福島県立医科大学 卵巣癌組織型鑑別方法
CN110880356A (zh) * 2018-09-05 2020-03-13 南京格致基因生物科技有限公司 对卵巢癌进行筛查、诊断或风险分级的方法和装置
WO2020092808A1 (en) * 2018-10-31 2020-05-07 Regents Of The University Of Minnesota Methods for predicting a response to bevacizumab or platinum-based chemotherapy or both in patients with ovarian cancer
US11610679B1 (en) 2020-04-20 2023-03-21 Health at Scale Corporation Prediction and prevention of medical events using machine-learning algorithms
CN112164474B (zh) * 2020-07-14 2024-05-24 中国矿业大学 一种基于自表达模型的药物敏感性预测方法
US12094582B1 (en) 2020-08-11 2024-09-17 Health at Scale Corporation Intelligent healthcare data fabric system
US12080428B1 (en) 2020-09-10 2024-09-03 Health at Scale Corporation Machine intelligence-based prioritization of non-emergent procedures and visits
US20240344138A1 (en) * 2021-03-25 2024-10-17 Feng Biosciences, Inc Targeted therapies in cancer
WO2022256743A1 (en) * 2021-06-04 2022-12-08 Cedars-Sinai Medical Center Use of cancer cell expression of cadherin 12 and cadherin 18 to treat bladder cancers
CN113667752A (zh) * 2021-09-09 2021-11-19 菲思特(上海)生物科技有限公司 一种用于柔红霉素代谢标志物的检测试剂盒及其检测方法和应用
WO2026015087A1 (en) * 2024-07-12 2026-01-15 National University Of Singapore A method for determining a subject's responsiveness to treatment with a vegf inhibitor

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
EP0430881A3 (en) 1989-11-29 1991-10-23 Ciba-Geigy Ag Photochromic compounds, process for their preparation and their use
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
JP2775346B2 (ja) 1992-04-03 1998-07-16 アプライド バイオシステムズ，インコーポレイテッド プローブ構成物および方法
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5470710A (en) 1993-10-22 1995-11-28 University Of Utah Automated hybridization/imaging device for fluorescent multiplex DNA sequencing
GB9401833D0 (en) 1994-02-01 1994-03-30 Isis Innovation Method for discovering ligands
WO1997027317A1 (en) 1996-01-23 1997-07-31 Affymetrix, Inc. Nucleic acid analysis techniques
GB9507238D0 (en) 1995-04-07 1995-05-31 Isis Innovation Detecting dna sequence variations
US5661028A (en) 1995-09-29 1997-08-26 Lockheed Martin Energy Systems, Inc. Large scale DNA microsequencing device
US6998234B2 (en) 2000-11-03 2006-02-14 Oncotech, Inc. Methods for cancer prognosis and diagnosis relating to tumor vascular endothelial cells
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
WO2004108896A2 (en) 2003-06-03 2004-12-16 The Board Of Trustees Of The University Of Arkansas Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
JP4682152B2 (ja) 2003-12-31 2011-05-11 ザ・ペン・ステート・リサーチ・ファンデーション 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法
US20080113874A1 (en) 2004-01-23 2008-05-15 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
CA2563074C (en) 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
BRPI0511088A (pt) 2004-05-14 2007-12-26 Monica Nister identificação e caracterização de um subconjunto de glioblastomas sensìveis ao tratamento com imatinib
AU2005263972A1 (en) 2004-07-23 2006-01-26 Astrazeneca Ab Method of predicting the responsiveness of a tumor to erbB receptor drugs
JP2008518610A (ja) 2004-11-03 2008-06-05 アルマック ダイアグノスティックス リミテッド トランスクリプトームマイクロアレイ技法およびそれを使用する方法
US7862995B2 (en) 2004-12-10 2011-01-04 Targeted Molecular Diagnostics Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
US20080305962A1 (en) 2005-07-29 2008-12-11 Ralph Markus Wirtz Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapies
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US7919261B2 (en) 2005-12-05 2011-04-05 Merck Sharp & Dohme Corp. Methods for predicting treatment response based on the expression profiles of protein and transcription biomarkers
JP2009524438A (ja) 2006-01-27 2009-07-02 トライパス イメージング インコーポレイテッド 卵巣癌を有する可能性の高い患者を同定するための方法およびそのための組成物
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
EP2074226A2 (en) 2006-09-19 2009-07-01 Novartis AG Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
NZ582941A (en) 2007-08-13 2012-05-25 Almac Diagnostics Ltd A 3' -based sequencing approach for microarray manufacture
WO2009061800A2 (en) * 2007-11-09 2009-05-14 Genentech, Inc. Methods and compositions for diagnostic use in cancer patients
WO2009149297A1 (en) 2008-06-04 2009-12-10 The Arizona Board Regents, On Behalf Of The University Of Arizona Diffuse large b-cell lymphoma markers and uses therefor
ES2552937T3 (es) 2008-06-06 2015-12-03 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Factor de predicción de supervivencia para linfoma difuso de células B grandes
CA2730614A1 (en) 2008-07-16 2010-01-21 Dana-Farber Cancer Institute Signatures and pcdeterminants associated with prostate cancer and methods of use thereof
JP5606438B2 (ja) 2008-07-23 2014-10-15 エフ．ホフマン−ラ ロシュ アーゲー 抗血管新生療法を受容可能な被験体の同定
DK2368118T3 (da) 2008-12-23 2013-11-25 Merck Patent Gmbh Biomarkører til inhibitorer med anti-angiogen aktivitet
WO2010088688A2 (en) 2009-02-02 2010-08-05 Biotheranostics, Inc. Diagnosis of in situ and invasive breast cancer
EP2425020A4 (en) 2009-05-01 2016-04-20 Genomic Health Inc GENE EXPRESSION PROFILE GORITHM AND TEST OF PROBABILITY OF REPRODUCTION OF COLORECTAL CANCER AND RESPONSE TO CHEMOTHERAPY
US7615353B1 (en) * 2009-07-06 2009-11-10 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
KR101557545B1 (ko) 2009-09-17 2015-10-06 에프. 호프만-라 로슈 아게 암 환자에서 진단 용도를 위한 방법 및 조성물
EP2975399B1 (en) 2010-09-15 2022-05-11 Almac Diagnostic Services Limited Molecular diagnostic test for cancer
AU2011352167A1 (en) 2010-12-28 2013-07-11 Caris Mpi, Inc. Molecular profiling for cancer
US10260097B2 (en) 2011-06-02 2019-04-16 Almac Diagnostics Limited Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent
CA2862835A1 (en) 2012-01-13 2013-07-18 Genentech, Inc. Biological markers for identifying patients for treatment with vegf antagonists
HK1214633A1 (zh) * 2012-12-03 2016-07-29 Almac Diagnostics Limited 癌症的分子诊断测试

Also Published As

Publication number Publication date
AU2015213844A1 (en) 2016-09-15
GB201409479D0 (en) 2014-07-09
KR20160117606A (ko) 2016-10-10
BR112016018044A2 (pt) 2018-02-20
JP2017506506A (ja) 2017-03-09
US20170073761A1 (en) 2017-03-16
WO2015118353A1 (en) 2015-08-13
EP3102700A1 (en) 2016-12-14
US10280468B2 (en) 2019-05-07
CN106164296A (zh) 2016-11-23

Similar Documents

Publication Publication Date Title
US10280468B2 (en) Molecular diagnostic test for predicting response to anti-angiogenic drugs and prognosis of cancer
US11091809B2 (en) Molecular diagnostic test for cancer
AU2012261820B2 (en) Molecular diagnostic test for cancer
US11254986B2 (en) Gene signature for immune therapies in cancer
EP2619574B1 (en) Molecular test for predicting responsiveness to dna-damage therapeutic agents in individuals having cancer
AU2012261820A1 (en) Molecular diagnostic test for cancer
US20160222459A1 (en) Molecular diagnostic test for lung cancer
US20160222460A1 (en) Molecular diagnostic test for oesophageal cancer
WO2017216559A1 (en) Predicting responsiveness to therapy in prostate cancer
US20170088902A1 (en) Expression profiling for cancers treated with anti-angiogenic therapy

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20200211

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: T-6-6-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20250218